James L. Kerwin

**** ******* ****** *, ******** Oaks CA 91320

act6dg@r.postjobfree.com • Cell 310-***-****

OBJECTIVE

Editor/writer/project manager in an area related but not limited to human health and (alternative) medicine, drug development and detection, mass spectrometry, environmental science, science policy, political analysis and policy.

EXPERIENCE

Sanovas, Inc. San Rafael, CA

Medical/technical writer Aug. 2011 to present

Literature reviews, white papers, RO1 proposals, monographs on human health policy, manuscript & proposal editing

University of California, Los Angeles, School of Medicine, Radiology

Medical/technical writer Feb. 2014 to present

Literature reviews, white papers, RO1 proposals, monographs on human health policy, manuscript & proposal editing

Private Health Management

Medical/technical writer March 2013 to present

Literature reviews, white papers, RO1 proposals, monographs on human health policy, manuscript & proposal editing

Drug Testing & Analysis

John Wiley & Sons

Perspectives and Review (Spotlight) Editor Sept. 2010 to present

Periodic perspective and/or review articles - Detection and analysis of medicinal compounds and illicit drugs. Policy and pharmaceutical issues.

House Ear Institute/Clinic Los Angeles, CA

July 2007-February 2010

Directed mass spectrometry facility for studies related to hearing disorders. Consultation with MD/PhD’s for strategies related to new approaches to drug development and limitation of secondary effects of existing drugs.

Oct 2006 – May 2007 USC, School of Pharmacy Los Angeles, CA

Manager, Analytical Core

Directed analytical chemistry experiments for a multi-institutional grant examining the role of steroids in Alzheimer’s disease using mass spectrometry, custom gene arrays, and ELISA for steroids and proteins.

2002–2005 UCLA, Biological Chemistry Los Angeles, CA

Manager, Proteomics and Mass Spectrometry Facility

Launched a new facility for characterization of proteins and peptides.

Advised over 200 academic and commercial laboratories on mass spectrometric analysis of proteins.

Supervised and administered all aspects related to daily operation, budget, and long-term strategy for the facility.

2000–2002 Cornell University, Biotechnology Department Ithaca, NY

Director, Mass Spectrometry Facility

Orchestrated development of a new facility for characterization of a wide variety of biological molecules and inorganic polymers.

Developed a customer base at Cornell and elsewhere on the east coast for the facility by lectures and direct contact with individual users.

Conceived novel approaches for characterization of a wide variety of molecules for over 100 laboratories.

1991–1999 University of Washington, Department of Botany Seattle, WA

Assistant/Associate Research Professor

Received grants from the National Institutes of Health, the World Health Organization, and private companies to develop a microbial mosquito pathogen.

Federal (USEPA) and state registration, large scale production, and aerial application of this pathogen.

Development of novel techniques for analysis of small molecules using new mass spectrometry instruments.

EDUCATION

Ph.D., Botany

University of Washington, Department of Botany Seattle, WA

M.S., Botany

University of Washington, Department of Botany Seattle, WA

B.A., Molecular biology

Pomona College Claremont,CA

EDITORIAL

Founding editorial board member

Drug Testing and Analysis, 2008-present.

FUNDING SOURCES

Multiple grants (> 3 million dollars direct costs) from the National Institutes of Health, Department of Health State of California, the World Health Organization, and pharmaceutical companies for basic and applied research on development of novel drugs to treat human fungal infections, and commercial development of a biological control agent for mosquitoes.

SKILLS

Administration/ technical writing/ laboratory and facility director

Prinicipal investigator for over 15 years involving development of biological control of mosquitoes on projects wholly supported by state and federal grants and private companies, including the National Institutes of Health, the World Health Organization, California vector control agencies, and a European pharmaceutical company. This involved supervision of and financial support for 6-22 people at any one time.

Collaboration with the Pasteur Institut (Paris) funded by a pharmaceutical company (now part of Novartis) for 3 years on identification of novel drugs for treatment of human pathogenic fungi.

Set up purchase of major instrumentation (mass spectrometry) facility organization, technical training and supervision, budget administration and project design for over two hundred labs/personnel at Cornell, UCLA and the House Ear Institute.

Designed and supervised all safety tests required for California/Florida State and Federal (USEPA) registration of 3 formulations of a microbial agent (Lagenidium giganteum) for mosquito control (over 1200 pages of documentation).

Medical writer for bioengineering firm (Sanovas, San Rafael) and UCLA Radiology Department.

PATENT

James L. Kerwin and Robert K. Washino. Artificial culture of the sexual stage of Lagenidium giganteum. Patent No. 4,687,744 - Aug. 18, 1987

SELECTED PUBLICATIONS (> 65)

3. Kerwin JL 1982 Chemical control of the germination of asexual spores of Entomophthora culicis, a fungus parasitic on dipterans. J Gen Microbiol 128: 2179-2186.

6. Kerwin JL and Washino RK 1983 Sterol induction of sexual reproduction in Lagenidium giganteum. Exp Mycol 7: 109-115.

15. Kerwin JL and Washino RK 1986 Cuticular regulation of host recognition and spore germination by entomopathogenic fungi. In: (RA Samson, JM Vlak and D Peters eds), Fundamental and applied aspects of invertebrate pathology, pp 423-425. Foundation 4th Internatl Coll Invertebr Pathol, Wageningen, The

Netherlands.

18. Kerwin JL Simmons CA and Washino RK 1986 Eicosanoid regulation of oosporogenesis by Lagenidium giganteum. Prostagland Leuko Med 23: 173-178.

19. Kerwin JL 1987 Fatty acids and fungal development: Structure-activity relationships. In: (G Fuller and WD Nes eds), Ecology and Metabolism of Plant Lipids, pp 329-342. Amer Chem Soc Symp Series No 325. ACS, Wash DC.

22. Kerwin JL Dritz DA and Washino RK 1988 Nonmammalian safety tests for Lagenidium giganteum

(Oomycetes:Lagenidiales). J Econ Entomol 81: 158-171.

23. Kerwin JL and Washino RK 1988 Field evaluation of Lagenidium giganteum (Oomycetes:Lagenidiales) and description of a natural epizootic involving a new isolate of the fungus. J Med Entomol 25: 452-460.

27. Kerwin JL Grant DF and Berbee ML 1990 Specific induction of encystment of Lagenidium giganteum zoospores by concanavalin A and derivatives of chitin and chitosan. Protoplasma 161: 43-51.

31. Kerwin JL 1994 The evolution of structure and function of fatty acids and their metabolites. In (WD Nes ed) Isopentenoids and other Natural Products - Evolution and Function. American Chemical Society Symposium Series 562, pp. 163-201.

32. Berbee ML and Kerwin JL 1993 Ultrastructural and light microscopic localization of carbohydrates and peroxidase/catalases in Lageniidum giganteum zoospores. Mycologia 85: 734-743.

33. Kerwin JL Tuininga AR and Ericsson LH 1994 Identification of molecular species of glycerophospholipids and sphingomyelin using electrospray mass spectrometry. J Lipid Res 35: 1102-1114.

37. Kerwin JL Dritz DA and Washino RK 1994 Pilot scale production and application in wildlife ponds of Lagenidium giganteum (Oomycetes: Lagenidiales). J Amer Mosq Control Assoc 10: 451-455.

38. Kerwin JL Tuininga AR Wiens AM Wang JC Torvik JJ Conrath JK and MacKichan JK 1995 Isoprenoid-mediated changes in the glycerophospholipid molecular species of the sterol auxotrophic fungus Lagenidium giganteum. Microbiology 141: 399-410.

39. Woodring JL Kaya HK and Kerwin JL 1995 Lagenidium giganteum in Culex tarsalis larvae: Production of infective propagules. J Invertebr Pathol 66: 25-32.

40. MacKichan J Thomsen L Kerwin J Latge J-P and Beauvais 1995 Unsaturated fatty acids are the active molecules of a glucan synthase inhibitory fraction isolated from Entomophthoralean protoplasts. Microbiology 141: 2757-2762.

44. Gu M Kerwin JL Watts J and Aebersold R 1997 Ceramide profiling of complex lipid mixtures by electrospray ionization mass spectrometry. Anal Biochem 244: 347-356.

49. Kerwin JL and Semon MJ 1998 Bioassay methods for fungi and Oomycetes. In: Methods in Chemical Ecology. J Millar and K Haynes eds. pp. 142-178, Chapman & Hall, New York.

52. Kerwin JL 1997 Profiling peptide adducts of oxidized N-acetyldopamine by electrospray mass spectrometry. Rapid Communications in Mass Spectrometry 11: 557-566

61. Kerwin J 2005 Lagenidium giganteum (Oomycetes) In :Biological Control of Mosquitoes (T. Floore ed) AMCA.

62. Guo S Ferl GZ Deora Riedinger MYin S Kerwin JL Loo JA and Witte O 2004 A tyrosine phosphorylation site in Btk selectively regulates the efficiency of B cell calcium signaling by altering PLC activation. Proc Nat Acad Sci. 101: 141**-*****

63. Kerwin JL Wu S Webster P 2015 Relation of protein expression to antibiotic resistance by human pathogenic bacteria. (Submitted).

64. Kerwin JL 2010 The asterisk chronicles: A short history of steroid use and analysis. DOI 10.1002/dta.184 Drug Testing & Analysis 2: 456-459.

65. Kerwin JL 2011 Doors of Deception: Diaspora of Designer Drugs. Drug Testing & Analysis.

3: 527–531.

66. Kerwin JL January 2013 Editor of Special Issue: Cannabinoids Part I – Legal policies and physiological effects. Drug Testing & Analysis 5: 1-67..

68. Siva Wu, Marc M. Baum, James Kerwin, Debbie Guerrero, Simon Webster,

Christoph Schaudinn, David VanderVelde and Paul Webster 2014 Biofilm-specific extracellular matrix proteins of non-typeable Haemophilus influenza. Pathogens and Disease 1–18.

69.

Li, Wenzhou; Kerwin, James; Schiel, John; Formolo, Trina; Davis, Darryl; Mahan, Andrew; Benchaar, Sabrina. 2015. Structural Elucidation of Post-Translational Modifications in Monoclonal Antibodies.

ACS BooksBook: "Biopharmaceutical Characterization”. Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2. Biopharmaceutical Characterization: The NISTmAb Case Study; Schiel, et al.; ACS Symposium Series; American Chemical Society: Washington, DC, 2015. pp. 119-183. https://mail.google.com/mail/u/0/?tab=wm#sent/150fddda972a0517?projector=1

REFRENCES

Available upon request.

Contact this candidate